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Abstract
Objective. To assess the responsiveness of clinical outcome measures in musculoskeletal SLE compared with US.
Methods. A prospective pilot study was conducted in consecutive SLE patients with inflammatory musculoskeletal
symptoms. Clinical assessments including SLEDAI, BILAG, 28 tender and swollen joint counts, physician and patient
visual analogue scales (VAS), and US were performed at 0, 2 and 4 weeks following 120 mg i.m. methylprednisolone
acetate. Responsiveness was analysed using changes and effect sizes using Cohen’s criteria.
Results. Twenty patients were recruited. Fifteen out of 20 had clinical swelling at baseline. All clinical and US param-
eters were significantly improved at week 4 (all P 4 0.01). Musculoskeletal-BILAG score improved in 16/20.
Musculoskeletal-SLEDAI improved in 7/20. SLE responder index 4 criteria were assessed in 19 patients with SLEDAI
54 at baseline and were met in 9/19 at 4 weeks. Effect sizes at 4 weeks were large (>0.5) for US, physician VAS and
BILAG, and medium (>0.3) for joint counts and SLEDAI. Large effect sizes for improvement in US grey-scale and power
Doppler were observed in both SLE responder index 4 responders (r=0.51 and 0.56, respectively) and non-re-
sponders (r=0.62 and 0.59, respectively) at 4 weeks.
Conclusion. This is the first study to measure the responsiveness of clinical outcome measures in musculoskeletal SLE
against an objective inflammation measure. BILAG and physician VAS were the most responsive clinical instruments. US
was highly responsive in musculoskeletal SLE, while SLEDAI and joint counts appeared suboptimal for detection of
improvement. These results suggest that clinical trials based on the SLEDAI and SLE responder index 4 may underesti-
mate the efficacy of therapy in SLE.
Key words: systematic lupus erythematosus, lupus arthritis, BILAG, SLEDAI, synovium, tendons and ligaments,
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Rheumatology key messages
. US was highly responsive for the musculoskeletal manifestations of SLE.
. Most clinical outcome measures were less responsive than US; SLEDAI and SLE responder index 4 may under-
estimate response.
. BILAG-2004 and physician visual analogue scales appeared more responsive than SLEDAI-2K and SLE
responder index 4 for musculoskeletal SLE.
Introduction
Inflammatory musculoskeletal features are common in
SLE, being the first presenting symptom in around 50%
of cases and affecting up to 95% of patients at some time
[1, 2]. Joint pain in SLE has a significant impact on quality
of life and results in loss of function [35]. Accordingly,
musculoskeletal disease is a common reason for inclusion
into clinical trials.
Recent phase III trials of many putative treatments in non-
renal SLE have been negative (with the exception of
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belimumab [6]). This has led to questions over the most ap-
propriate outcome measures to use in SLE trials. Also, in
clinical practice, it is equally important to differentiate patients
with good or incomplete responses to therapy for treat-to-
target approaches and to minimize glucocorticoid use [7].
While non-renal SLE trials included many different types of
organ involvement, musculoskeletal disease was most
common. For example, in the pooled data from the study
of belimumab in subjects with SLE, BLISS52 and BLISS76
trials, 1008/1684 (60%) patients had musculoskeletal (MSK)-
BILAG A or B at baseline; 991/1684 (59%) had mucocuta-
neous BILAG A or B; and 272/1684 (16%) had haematology
A or B; with lower percentages for other organ systems. In
the phase III Efficacy and safety of subcutaneous tabalumab
in patients with SLE (ILLUMINATE) study, at baseline, 81% of
patients had musculoskeletal activity on the SLEDAI [8].
In SLE, outcome measures must account for disease
activity in many different organs. For this reason, less
detail is included for each organ compared with more
organ-specific instruments such as the 28 joint count
used in RA. The SLEDAI and BILAG, and composite end-
points derived from them such as the SLE responder
index 4 (SRI-4) and BILAG-based composite lupus as-
sessment, are commonly used in trials.
For musculoskeletal involvement, the SLEDAI-2K [9] is
binary, scoring 4 points for tenderness with swelling, effu-
sion, warmth or erythema in two or more joints in the past
30 days, and none for lesser degrees of arthritis. This scoring
means that patients with a high level of disease activity at
baseline who have a substantial improvement may be con-
sidered non-responders. The BILAG-2004 index [10] is semi-
quantitative with 4 grades for each active organ system
assessed. For the musculoskeletal domain, BILAG A (the
highest score) requires observed active synovitis in more
than two joints with marked loss of functional range of move-
ments. BILAG B is scored for tendonitis/tenosynovitis or
active synovitis in more than one joint (observed or through
history) with some loss of functional range of movement (or
improving BILAG A disease). BILAG C is scored for inflam-
matory pain (e.g. with morning stiffness) without synovitis (or
improving BILAG B disease). Pain without inflammatory
symptoms (e.g. pain that clinically appears to be because
of OA) is scored as BILAG D or E, as are patients with pre-
vious joint inflammation but no current symptoms. Assigning
these grades is dependent on the skill of the assessor, and in
both these indices, the assessor must only score symptoms
that are deemed to be due to active SLE rather than other
pathologies, which is known to be a difficult distinction for
arthralgia in many inflammatory arthritides.
Joint counts and visual analogue scales (VAS) have also
been used in many SLE trials, but with limited independ-
ent validation [11]. Musculoskeletal US provides an ob-
jective measure of synovitis that has already been
shown to have face and construct validity in SLE [12].
We recently showed that the BILAG and SLEDAI are spe-
cific but not sensitive for the detection of synovitis that is
US-confirmed and associated with worse symptoms and
serological abnormality [13]. These various instruments
have never been compared longitudinally.
The objective of this study was therefore to compare
the internal responsiveness of a range of clinical outcome
measures and US in SLE patients receiving a therapy of
known efficacy (glucocorticoids).
Methods
Patients
Twenty patients fulfilling the SLICC 2012 diagnostic cri-
teria [14] for SLE were recruited in Leeds if they had been
prescribed 120 mg i.m. methylprednisolone acetate for
active musculoskeletal disease that day as part of routine
care. This dose and method of administration is com-
monly used for musculoskeletal flares in the UK. Briefly,
other eligibility criteria included: stable doses of NSAID,
DMARDs and glucocorticoids (up to prednisolone45 mg/
day or equivalent) for at least 6 weeks prior to entry visit.
CCP antibody-positive patients and those with improving
disease were excluded. Clinical assessment and US were
performed on the day of i.m. glucocorticoid treatment and
repeated after 2 and 4 weeks to assess responsiveness.
The study was approved by the local ethics committee
and informed written consent was obtained from all pa-
tients (Leeds East Research Ethics Committee 10/H1306/
88). We included all referred patients on an intent-to-treat
basis (i.e. we did not withdraw patients based on their
baseline clinical and US assessment).
Clinical and laboratory assessment
The clinical assessments were performed by trained
rheumatologists who were blinded to the US assessment
and were independent of the glucocorticoid treatment de-
cision. SLE was assessed using BILAG-2004 [10] and
SLEDAI-2K 30 days [15]. Joint disease was assessed
using 28 tender joint counts (TJCs) and swollen joint
counts (SJCs), painful joint count, physician musculoskel-
etal VAS, patient musculoskeletal disease activity VAS
and minutes of early morning stiffness (EMS). BILAG-
2004 numerical scores were calculated using the formula
A = 12, B = 8, C = 1, D/E = 0 [16]. The BILAG-2004 is as-
sessed over the previous 28 days. The SLEDAI-2K and
SRI-4 have been validated measuring symptoms over
the previous 10 or 30 days [17, 18]. Response to depome-
drone is typically seen within a few days. For the purposes
of this study we allowed a 5-day window for follow-up
study visits and for patients who reported a rapid im-
provement in symptoms within a few days of the injection
and for the majority of the period since the baseline visit to
have a 4 week response at the last assessment.
Patients were tested at baseline for routine inflamma-
tory and serological markers. SRI-4 was calculated as
previously described [19]. SRI-4 response criteria were
met if the patient had: at least a 4-point reduction in the
SLEDAI-2K, no worsening in physician VAS and no wor-
sening in BILAG.
US assessment
US [grey-scale (GS) and power Doppler (PD)] was per-
formed using a General Electric Logiq E9 with multi-linear
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615 MHz transducer. Two sonographers were trained and
experienced in musculoskeletal US and were blinded to
patients’ clinical evaluation and also independent of the
glucocorticoid treatment decision. PD was assessed with
the highest gain level without background noise, pulse
repetition frequency of 750 Hz and medium wall filter.
Bilateral hands and wrists were scanned. All joints in the
hand and wrists were examined using the standard ap-
proach of examining the following: radio-carpal, inter-
carpal and ulnar-carpal joints, first to fifth MCP joints and
first to fifth PIP joints. Bilateral tendon sheaths including the
extensor carpi ulnaris and second to fifth flexor digitorium
tendon sheaths were assessed for the presence of teno-
synovitis. The synovitis GS and PD were scored using the
OMERACT definitions and proposed semiquantitative 03
scale [2022]. The GS scoring was: 0 = no synovial hyper-
trophy, 1 = mild hypertrophy, 2 = moderate hypertrophy and
3 = severe hypertrophy. The PD scoring was: 0 = absence
of signal, no intra-articular flow, 1 = mild hyperaemia, one or
two vessels signal (including one confluent vessel),
2 = moderate hyperaemia, (>grade 1) and <50% of GS
area and 3 = marked hyperaemia, vessels signal in more
than half of the synovial area. Tenosynovitis was defined
according to the OMERACT criteria [22] and the GS and PD
signal scored using semi-quantitative 03 scale system
(0 = normal, 1 = mild, 2 = moderate and 3 = severe) [23]. US
abnormalities (62 areas) were summarized as total GS, PD,
erosions and tenosynovitis, as well as numbers of joints
with abnormal GS (52) or PD (51), erosions or tendons
with tenosynovitis (as any GS and/or PD abnormality in the
tendon sheath).
Statistical analysis
Overall clinical characteristics (demographics, therapies,
clinical joint assessments and immunological parameters)
and US characteristics were summarized for each group
using proportions of patients or median and interquartile
range as appropriate.
A variety of methods have been used to calculate effect
sizes to measure internal responsiveness. Standardized
response means may be used for parametric variables.
The candidate outcome measures in this study included
parametric, ordinal and categorical variables. We there-
fore used effect sizes calculated from a paired non-
parametric test instead of paired t-tests as usually used
to calculate effect size statistics [24]. Change in continu-
ous variables was assessed using Wilcoxon Signed Ranks
test. Effect size was calculated using standardized test
statistic, Z, using the formula r= Z/sqrt(n1 + n2). Effect
sizes were judged using Cohen’s Criteria as large
(>0.5), medium (>0.3) or small (>0.1) [25].
Results
Baseline characteristics
All 20 patients were female and ANA positive. Mean (S.D.)
age was 49.7 years (14.1) and mean (S.D.) disease duration
85 months (22). Eleven of 20 (55%) were receiving NSAID
therapy. Fourteen were on stable-dose hydroxychloro-
quine, of whom three were also on stable-dose MTX or
MMF and one was on epratuzumab. Three patients
received MTX or MMF without HCQ. Three patients
TABLE 1 Summaries of clinical and US assessments at weeks 0, 2 and 4
Outcome measure Week 0 Week 2 Week 4 Change week 2 Change week 4
MSK-BILAG, n (%)
A 7/20 (35) N/A 1/20 (5) N/A
B 8/20 (40) 2/20 (10) Improved 16/20 (80%)
C 5/20 (25) 9/20 (45) Same 4/20 (20%)
D 7/20 (35) Worse 0/20 (0%)
BILAG-MSK (A = 12, B = 8, C = 1, D = 0) 8 (3, 12) N/A 1 (0, 1) N/A 7 (8, 1)
SLEDAI arthritis present, n (%) 19/20 (95) N/A 10/20 (50) N/A Improved 7/20 (35%)
Same 13/20 (65%)
SLEDAI arthritis 4 (4, 4) N/A 2 (0, 4) N/A 0 (4, 0)
TJC (028) 8 (4, 12) 4 (1, 14) 2 (1, 11) 3 (4, 3) 4 (6, 1)
SJC (028) 2 (0, 5) 0 (0, 1) 0 (00) 1 (3, 0) 2 (3, 0)
Symptomatic joint count 15 (6, 22) 2 (0, 13) 4 (1, 15) 7 (19, 0) 6 (14, 1)
EMS (min) 25 (0, 60) 5 (0, 45) 3 (0, 41) 0 (21, 0) 0 (24, 0)
Patient VAS (mm) 57 (30, 79) 30 (9, 40) 33 (8, 49) 23 (29, 10) 22 (52, 2)
Physician VAS (mm) 55 (35, 68) 23 (5, 50) 15 (5, 35) 24 (45, 15) 31 (45, 15)
US—total PD 8 (2, 26) 1 (0, 6) 1 (0, 1) 8 (27, 2) 8 (10, 2)
US—total GS 19 (9, 43) 13 (5, 24) 8 (2, 13) 12 (23, 4) 10 (21, 3)
Joints with US synovitis 5.5 (1, 9) 3 (1, 8) 1 (0, 4) 7 (10, 3) 5 (12, 2)
All values presented are median (interquartile range) unless otherwise stated. MSK-BILAG: musculoskeletal element of BILAG;
N/A: not applicable; TJC: tender joint count in 28 joints; SJC: swollen joint count in 28 joints; symptomatic joint count: number
of joints indicated as painful or stiff by patients on a graphical questionnaire; EMS: early morning stiffness; PD: total US power
Doppler score; GS: total US greyscale score; joints with US synovitis: number of joints scoring either GS >1 or PD >0; VAS:
visual analogue scales.
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were not on HCQ or oral immunosuppressants. Three pa-
tients received stable-dose prednisolone 45 mg/day.
Fifteen of 20 patients had clinical joint swelling at baseline.
The others all had either US synovitis (GS in 18/20, PD in
17/20) or >60 min of EMS, or new activity in other organ
systems coincident with the onset of joint pain.
Changes in outcome measures
At 4 weeks there was a substantive and significant im-
provement in all clinical and US parameters measured
(all P< 0.025, Table 1). However, 65% of patients still
had symptoms with BILAG AC. Sixteen of 20 patients
had improvement by at least one MSK-BILAG grade, but
only 7/20 had improvement in the musculoskeletal
SLEDAI component. Residual symptoms were confirmed
by TJC and symptomatic joint count, morning stiffness,
and patient and physician VAS. On 4-week US there
was a large reduction in PD. PD was present in nine pa-
tients at 4 weeks, but with a total score of <2 in eight of
these (Fig. 1). GS scores were significantly reduced but
higher than PD post-treatment, being present at52 in 13/
20 patients.
Changes in these parameters at 2 weeks were more
variable. TJCs, SJCs and EMS minutes had numerically,
but not statistically, significantly improved. VAS showed a
partial but significant improvement. US parameters had all
significantly improved at 2 weeks, although to lesser
degree than at 4 weeks.
Effect sizes ordered according to magnitude are shown
in Table 2. At both 2 and 4 weeks, physician VAS had the
largest effect size, although it must be noted that this as-
sessment was not blinded to time point and may be more
susceptible to observer bias than the other variables.
Other than physician VAS, at 2 weeks only changes in
US showed large effect sizes. Changes in clinical vari-
ables were only smallmedium.
At week 4, effect sizes remained large for US and phys-
ician VAS. They were medium for other clinical variables
(joint counts, EMS, patient VAS). Effect sizes for muscu-
loskeletal components of BILAG and SLEDAI differed: the
effect for MSK-BILAG was of a similar magnitude to US.
Although the MSK-SLEDAI significantly improved, its
effect size was substantially smaller than for BILAG, US
and physician VAS.
Comparison of SLEDAI responders and non-
responders
The 19 patients with an MSK-SLEDAI score of at least 4
points at baseline were grouped into SRI-4 responders
(n= 9) and SRI-4 non-responders (n= 10). SRI-4 and
change in MSK-SLEDAI were generally equivalent in this
patient group. All SRI-4 responders also had improvement
in the musculoskeletal component of the SLEDAI except
for one who improved in other organ domains and had a
mixed response in musculoskeletal variables. All SRI-4
non-responders did not have improvement in the muscu-
loskeletal component of the SLEDAI. Full data are show in
supplementary Table S1, available at Rheumatology
online.
We then compared change in TJCs and SJCs, and US
GS and PD in each of these groups (Fig. 2). For TJCs and
SJCs there were large effect sizes in SRI-4 responders
(r=0.505 and 0.492, and P = 0.024 and 0.028, respect-
ively) and medium effect sizes in SRI-4 non-responders
(r=0.365 and 0.331, and P = 0.122 and 0.160, respect-
ively). For US, large effect sizes for improvements in both
GS and PD were observed in both SRI-4 responders
(r=0.517 and 0.564, and P = 0.021 and 0.021, respect-
ively) and SRI-4 non-responders (r=0.629 and 0.596,
and P = 0.008 and 0.012, respectively). In many cases the
size of the improvements in SRI-4 non-responders was
large. For example, a 70% improvement was seen in 30,
60, 40 and 70% of patients for TJCs, SJC, US GS and US
PD, respectively (supplementary Table S2, available at
Rheumatology online).
Discussion
In this study, we compared the internal responsiveness of
clinical outcome measures and US in SLE in patients
receiving a known efficacious therapy. All commonly used
clinical variables significantly improved by week 4 but there
was variation in responsiveness between them. BILAG-
2004 and physician VAS had similar responsiveness to
FIG. 1 Example US images
US images of MCP joint in an SLE patient at baseline and
4 weeks. Baseline image shows grade 3 power Doppler,
which has completely resolved at 4 weeks.
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US, but are more susceptible to observer bias. SRI-4
underestimated response, with substantial objective im-
provements in synovitis in SRI-4 non-responders. If repli-
cated in larger studies these results may have implications
for the design of clinical trials in SLE as well as routine
clinical practice.
A dilemma in clinical trials in SLE has been that many
therapies that appear to be effective in other contexts
have produced negative Randomized Control Trials.
There are many possible reasons for this, including the
recruitment of some ANA-negative patients and use of
active comparator arms. However, there are reasons to
believe that choice of outcome measures is at least
partly responsible for these discrepancies in the evidence
base. In the belimumab programme, phase II data using
the Safety of Estrogen in Systemic Lupus Erythematosus
National Assessment (SELENA)-SLEDAI were negative
[26]. The SRI was derived from these phase II data and
used to design a phase III trial, which produced the op-
posite result [18]. The rituximab Efficacy and safety of
rituximab in moderately-to-severely active SLE
(EXPLORER) study was negative for its BILAG-based pri-
mary and secondary endpoints, but had positive results in
post hoc analyses such as BILAG A flare rate [27, 28].
While the SRI has been highly successful in several clinical
trials, the response rates in the two phase III trials of beli-
mumab were rather low at 4358% vs 3444% for beli-
mumab and placebo, respectively [29]. The data we report
here show that the SRI-4 underestimates clinical improve-
ment in patients with arthritis and therefore may suggest
that clinical trials would show higher response rates and
greater differentiation of active and placebo arms if ima-
ging outcome measures, or more reponsive clinical out-
come measures, were used.
For effective treatment of SLE in the clinic it is essential
to be able to measure disease activity accurately, espe-
cially when using biologic therapies. An international task
force recently recommended treating to a target of low
disease activity in SLE, as well as minimizing glucocortic-
oid exposure [30]. The low disease activity target was rec-
ommended to use a validated lupus activity index and/or
organ-specific markers. Our results suggest that choice of
definition of disease activity could alter treatment deci-
sions, although this needs to be confirmed in longitudinal
studies. For example, the UK National Institute of Health
and Clinical Excellence criteria for belimumab mandate
that treatment should only be continued if there is at
least a 4-point reduction in the SLEDAI [31]. Our data in-
dicate that patients with musculoskeletal disease not
achieving this 4-point reduction may still have clinically
meaningful improvement, and physician VAS data sug-
gest that overall physician judgement may be a better
guide to response. Nevertheless, many other studies
show that patients with musculoskeletal symptoms but
not clinical joint swelling (not meeting BILAG A/B or
SLEDAI criteria) may have subclinical synovitis [12].
TABLE 2 Effect sizes for change at 2 and 4 weeks according to magnitude
Outcome measure No. pairs P Z Effect size Cohen criteria
Week 0week 2
Physician VAS 16 0.001 3.409 0.603 Large
GS score 16 0.002 3.13 0.571 Large
No. joints with US synovitis 16 0.011 3.160 0.559 Large
PD score 16 0.002 3.099 0.548 Large
Symptomatic joint count 10 0.047 1.988 0.445 Medium
Patient VAS 16 0.016 2.409 0.426 Medium
EMS (min) 16 0.046 1.997 0.353 Medium
SJC 16 0.059 1.889 0.334 Medium
TJC 15 0.274 1.093 0.200 Small
Week 0week 4
Physician VAS 20 <0.001 3.388 0.593 Large
MSK-BILAG numeric 20 0.008 3.643 0.576 Large
PD score 20 <0.001 3.627 0.573 Large
No. joints with US synovitis 20 0.001 3.627 0.573 Large
GS score 20 <0.001 3.503 0.554 Large
Symptomatic joint count 14 0.010 2.576 0.487 Medium
MSK-SLEDAI score 20 0.003 3.000 0.474 Medium
TJC 20 0.007 2.683 0.424 Medium
EMS (min) 20 0.012 2.527 0.400 Medium
SJC 20 0.007 2.425 0.383 Medium
Patient VAS 20 0.020 2.331 0.369 Medium
MSK-BILAG numeric calculated using A = 12, B = 8, C = 1, D = 0. MSK-SLEDAI score calculated using arthritis present in
previous 30 days = 4, arthritis absent = 0. P-values are results of Wilcoxon signed ranks test, Z: standardized test statistic,
effect size r calculated as r= Z/sqrt(2N). MSK-BILAG: musculoskeletal element of BILAG; MSK-SLEDAI: musculoskeletal
element of SLEDAI; EMS: early morning stiffness; GS score: total ultrasound grey scale score; PD score: total US power
Doppler score; VAS: visual analogue scales; SJC: swollen joint count; TJC: tender joint count.
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Hence in forming their judgement of response physicians
may wish to consider US in patients with ongoing inflam-
matory symptoms despite a degree of improvement.
Physician VAS appeared to be highly responsive in this
study. It must be noted that assessors were not blinded to
time point and this may affect subjective outcome meas-
ures due to observer bias. Observer bias may also affect
the BILAG ‘improving’ score, wherein synovitis that is still
present but determined to be improving results in a lower
BILAG score than if it is deemed to be stable or worsen-
ing. Furthermore, the BILAG is affected by the skill and
experience of the assessor. All our assessments were per-
formed by trained assessors experienced in SLE clinical
trials. An advantage of US is that it is more objective.
However, it is operator-dependent and may be more dif-
ficult to standardize in multicentre studies. Joint counts
were not as responsive as other instruments here, but
are easier to standardize in multicentre studies given
their widespread use in other inflammatory arthritis.
When first developed, the BILAG and SLEDAI were vali-
dated against the physician’s intention-to-treat and judge-
ment of overall disease activity. In our cross-sectional
study we noted that US synovitis is common in patients
without joint swelling and no clinical instrument could
detect this. This suggests that validation against an ob-
jective measure of disease activity would be more valu-
able. Although there is no other study focusing specifically
on musculoskeletal disease, one previous study com-
pared the sensitivity to change of five clinical instruments
for overall disease activity (SLAM, SLEDAI, BILAG,
ECLAM and Lupus Activity Index) [32]. Similar to our
study, in that paper the SLEDAI was less responsive
that the BILAG.
Our results suggest that an organ-specific outcome
measure may be more valuable in this common manifest-
ation. This has already been established in the other most
common manifestation of SLE: cutaneous disease. The
Cutaneous Lupus Activity and Severity Index (CLASI)
FIG. 2 Change in joint counts and US and SRI-4 response
Patients who had a MSK-SLEDAI score of 4 points at baseline were grouped according to whether they met the SRI-4
response criterion at the 4 week follow-up. P-values show the results of a Wilcoxon matched pairs test within each group
and effect size r. PD: total US power Doppler score; GS: total US grey-scale score; SRI-4: SLE responder index 4.
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[33] provides an organ-specific, continuous measure of
cutaneous disease activity. In recent clinical trials of sifa-
limumab and anifrolumab, the CLASI showed a high rate
of responsiveness [34, 35]. In our study, physician VAS
was more responsive than the musculoskeletal compo-
nent of the SLEDAI. Tender, swollen and symptomatic
joint counts had similar responsiveness to the SLEDAI,
but may be advantageous in multicentre trials in being
less dependent on the experience and opinion of the as-
sessor, and less susceptible to observer bias. The data in
this study and our previous larger cross-sectional study
demonstrate that joint counts and US findings vary more
than BILAG and SLEDAI grades. It is therefore likely that a
composite outcome measure could be designed for mus-
culoskeletal disease that offers similar advantages to the
CLASI. This is being determined in our future research.
One previous paper has also shown the potential advan-
tages of specific musculoskeletal outcome measures in
patients treated with belimumab [36]. The CLASI and
joint counts have also revealed nuances of response in
individual organ domains in patient subgroups after beli-
mumab therapy [37].
Our study has some limitations. Patient numbers were
relatively small. We used a single-centre design; this may
be important for tools that require training (e.g. BILAG) or
inter-observer standardization (US). Assessors were not
blinded to therapy or time point, which may have affected
some instruments. However, clinical and US assessors
were blinded to each other’s findings. Lastly, we have
not yet assessed external responsiveness—i.e. respon-
siveness compared with some external anchor [24].
Despite these limitations, our results are unique in com-
paring responsiveness to an objective standard and indi-
cate the limitations of existing tools for musculoskeletal
lupus. Our results suggest that an organ-specific outcome
measure for musculoskeletal disease would have advan-
tages in both clinical trials and routine clinical practice.
This is being definitively assessed in a larger longitudinal
study currently in progress.
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